2026
-
International Participants Center Offers Dynamic Global Programming and Networking
on
Read more: International Participants Center Offers Dynamic Global Programming and NetworkingThe International Participants Center (IPC) at the ATS 2026 International Conference will present a robust series of 12 multidisciplinary talks and gatherings open to all conference participants, May 16-19, during ATS 2026 Orlando. The IPC will also host kiosks representing more than a dozen international organizations and societies with representatives available for networking and conversations…
-
New Vaccine Adoption Strategies from Multi-Year Grant Initiative to be Shared at ATS 2026 Orlando
on
Read more: New Vaccine Adoption Strategies from Multi-Year Grant Initiative to be Shared at ATS 2026 OrlandoThe ATS is one of seven specialty societies awarded a grant by the Council of Medical Specialty Societies and CDC to increase COVID-19, influenza, and routine vaccination rates among high-risk adult patients in the United States. Data collection for this initiative wrapped in summer 2025, and the ATS is now using its findings to build…
-
ATS Assembly Meetings to Connect Members in Orlando
on
Read more: ATS Assembly Meetings to Connect Members in OrlandoThe 14 assemblies within the ATS will hold membership meetings at the International Conference inside Orlando’s Orange County Convention Center from 5–7 p.m. ET on Sunday and Monday, May 17-18.
-
Make the Most of Your Free Time for a Magical Orlando Experience
on
Read more: Make the Most of Your Free Time for a Magical Orlando ExperienceOrlando is a unique city in the Sunshine State, with world-famous theme parks, resorts, and gorgeous natural scenery. Before arriving at ATS 2026 Orlando this May, start planning to make the most of your free time!
-
Let Camp ATS Make the International Conference a Family Affair in Orlando
on
Read more: Let Camp ATS Make the International Conference a Family Affair in OrlandoCamp ATS has the kids covered while parents attend education sessions and network at ATS 2026 Orlando. The program offers a fun, safe, and engaging experience designed just for kids aged six months to 12 years, allowing adults to enjoy the International Conference worry-free.
-
ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPF
on
Read more: ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPFThe ATS 2026 International Conference will spotlight a wide range of recent investigative and clinical advances in the treatment of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), including the development of nerandomilast, the first FDA-approved therapy for IPF in over a decade. Susan K. Mathai, MD, spoke with ATS Conference News to preview…
-
ATS 2026 Orlando Spotlights Recent Advancements in Pediatric ILD Treatments
on
Read more: ATS 2026 Orlando Spotlights Recent Advancements in Pediatric ILD TreatmentsTreating pediatric patients with ILD or IPF can require unique treatment considerations and innovations compared with the treatment of adult populations. The relative rarity of pediatric patients with ILD reveals an urgent need for education among pediatric subspecialty providers and primary care physicians about how to diagnose and treat these diseases in collaboration with pediatric…
-
Explore the Latest Developments in Bronchiectasis During ATS 2026 Orlando
on
Read more: Explore the Latest Developments in Bronchiectasis During ATS 2026 OrlandoIn August 2025, clinicians and researchers who treat patients with bronchiectasis reached a significant milestone with the FDA approval of brensocatib, the first treatment developed for non-cystic fibrosis bronchiectasis in adults and pediatric patients aged 12 and older. In an interview with ATS Conference News, Dan Belz, MD, MPH, explained the significance of this milestone…
-
ATS 2026 Orlando Sessions Examine Recent Insights and Unique Challenges for Treating COPD
on
Read more: ATS 2026 Orlando Sessions Examine Recent Insights and Unique Challenges for Treating COPDRecent reports show that chronic obstructive pulmonary disease (COPD) was the fifth leading cause of death in the United States in 2023, with 141,733 deaths related to the disease during that year. Additionally, treatments for the disease incur annual medical costs of approximately $24 billion for adults aged 45 and older. Spyridon Fortis, MD, PhD,…
-
Health Equity and Health Disparities Lineup at ATS 2026 Orlando
on
Read more: Health Equity and Health Disparities Lineup at ATS 2026 OrlandoThe ATS 2026 International Conference offers a robust scientific program highlighting cutting-edge advancements in pulmonary, critical care, and sleep medicine. This includes several Postgraduate Courses, Scientific Symposia, and Meet the […]